Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop

Molecular Endocrinology

Volumn 29, Issue 2, 2015, Pages 213-223

  Patel, Rucha ^a   Bookout, Angie L ^b   Magomedova, Lilia ^a   Owen, Bryn M ^b   Consiglio, Giulia P ^a   Shimizu, Makoto ^b   Zhang, Yuan ^b   Mangelsdorf, David J ^b   Kliewer, Steven A ^c   Cummins, Carolyn L ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Banting and Best Diabetes Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; FIBROBLAST GROWTH FACTOR 21; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROIDOGENIC ACUTE REGULATORY PROTEIN; CHROMATIN; DEXAMETHASONE; FIBROBLAST GROWTH FACTOR; PROTEIN BINDING;

ADRENAL CORTEX CELL; ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOSTERONE RELEASE; CORTICOTROPIN BLOOD LEVEL; GENE LOCUS; GLUCONEOGENESIS; HISTONE ACETYLATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIVER CELL; MALE; METABOLIC REGULATION; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RECEPTOR BINDING; STARVATION; STEROIDOGENESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION REGULATION; ADRENAL CORTEX; ANIMAL; BASE PAIRING; BIOLOGICAL MODEL; BIOSYNTHESIS; C57BL MOUSE; CHROMATIN; CYTOLOGY; DRUG EFFECTS; HUMAN; LIVER; METABOLISM; TRANSGENIC MOUSE;

MUS;

ADRENAL CORTEX; ADRENOCORTICOTROPIC HORMONE; ANIMALS; BASE PAIRING; BINDING SITES; CHROMATIN; CORTICOSTERONE; DEXAMETHASONE; FIBROBLAST GROWTH FACTORS; GENETIC LOCI; GLUCOCORTICOIDS; HUMANS; LIVER; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PPAR ALPHA; PROTEIN BINDING; RECEPTORS, GLUCOCORTICOID; TRANSCRIPTION INITIATION SITE; TRANSCRIPTIONAL ACTIVATION;

EID: 84922331368     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2014-1259     Document Type: Article

References (54)

1. Inagaki T, Dutchak P, Zhao G, et al. Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415–425.
2. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos- Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 2007;5(6):426–437.
3. Potthoff MJ, Inagaki T, Satapati S, et al. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA. 2009; 106(26):10853–10858.
4. Gaich G, Chien JY, Fu H, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18(3):333–340.
5. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012;26(4):312–324.
6. Kharitonenkov A, Dunbar JD, Bina HA, et al. FGF-21/FGF-21 receptor interaction and activation is determined by βKlotho. J Cell Physiol. 2008;215(1):1–7.
7. Kurosu H, Choi M, Ogawa Y, et al. Tissue-specific expression of βKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF 21. J Biol Chem. 2007;282(37):26687–26695.
8. Ogawa Y, Kurosu H, Yamamoto M, et al. βKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci USA. 2007;104(18):7432–7437.
9. Fon Tacer K, Bookout AL, Ding X, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol. 2010;24(10):2050–2064.
10. Wittmers LE Jr, Haller EW. Effect of adrenalectomy on the metabolism of glucose in obese (C57 Bl/6J ob/ob) mice. Metabolism. 1983;32(12):1093–1100.
11. Dubuc PU. Interactions between insulin and glucocorticoids in the maintenance of genetic obesity. Am J Physiol. 1992;263(3 Pt 1): E550–E555.
12. Friedman JE, Sun Y, Ishizuka T, et al. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice. J Biol Chem. 1997;272(50):31475–31481.
13. Shimomura Y, Bray GA, Lee M. Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res. 1987;19(7):295–299.
14. Wei W, Dutchak PA, Wang X, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator- activated receptor gamma. Proc Natl Acad Sci USA. 2012; 109(8):3143–3148.
15. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41(3):595–611.
16. Bookout AL, de Groot MH, Owen BM, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med. 2013;19(9):1147–1152.
17. Fisher FM, Chui PC, Antonellis PJ, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes. 59(11):2781–2789.
18. Hale C, Chen MM, Stanislaus S, et al. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance. Endocrinology. 2012;153(1):69–80.
19. Adams AC, Astapova I, Fisher FM, et al. Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARα- dependent manner. J Biol Chem. 285(19):14078–14082.
20. Patel R, Patel M, Tsai R, et al. LXRβ is required for glucocorticoidinduced hyperglycemia and hepatosteatosis in mice. J Clin Invest. 2011;121(1):431–441.
21. Cummins CL, Volle DH, Zhang Y, et al. Liver X receptors regulate adrenal cholesterol balance. J Clin Invest. 2006;116(7):1902–1912.
22. Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF. High-throughput real-time quantitative reverse transcription PCR. Curr Protoc Mol Biol. 2006;Chapter 15:Unit 15.8.
23. Ding X, Boney-Montoya J, Owen BM, et al. βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012;16(3):387–393.
24. Horton JD, Shimano H, Hamilton RL, Brown MS, Goldstein JL. Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J Clin Invest. 1999;103(7):1067–1076.
25. Podvinec M, Kaufmann MR, Handschin C, Meyer UA. NUBIScan, an in silico approach for prediction of nuclear receptor response elements. Mol Endocrinol. 2002;16(6):1269–1279.
26. Liang Q, Zhong L, Zhang J, et al. FGF21 maintains glucose homeostasis by mediating the crosstalk between liver and brain during prolonged fasting. Diabetes. 2014;63(12):4064–4075.
27. Suemaru S, Hashimoto K, Hattori T, Inoue H, Kageyama J, Ota Z. Starvation-induced changes in rat brain corticotropin-releasing factor (CRF) and pituitary-adrenocortical response. Life Sci. 1986; 39(13):1161–1166.
28. Edwards AV, Jones CT. The effect of splanchnic nerve section on the sensitivity of the adrenal cortex to adrenocorticotrophin in the calf. J Physiol. 1987;390:23–31.
29. Engeland WC, Gann DS. Splanchnic nerve stimulation modulates steroid secretion in hypophysectomized dogs. Neuroendocrinology. 1989;50(2):124–131.
30. Owen BM, Ding X, Morgan DA, et al. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss. Cell Metab. 2014;20(4):670–677.
31. Grontved L, John S, Baek S, et al. C/EBP maintains chromatin accessibility in liver and facilitates glucocorticoid receptor recruitment to steroid response elements. EMBO J. 2013;32(11):1568–1583.
32. Shaffer PL, Jivan A, Dollins DE, Claessens F, Gewirth DT. Structural basis of androgen receptor binding to selective androgen response elements. Proc Natl Acad Sci USA. 2004;101(14):4758–4763.
33. Makino S, Kaneda T, Nishiyama M, Asaba K, Hashimoto K. Lack of decrease in hypothalamic and hippocampal glucocorticoid receptor mRNA during starvation. Neuroendocrinology. 2001;74(2): 120–128.
34. van den Berghe G. The role of the liver in metabolic homeostasis: implications for inborn errors of metabolism. J Inherit Metab Dis. 1991;14(4):407–420.
35. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptorα mediates the adaptive response to fasting. J Clin Invest. 1999;103(11):1489–1498.
36. Lemberger T, Saladin R, Vazquez M, et al. Expression of the peroxisome proliferator-activated receptor α gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem. 1996;271(3): 1764–1769.
37. Berglund ED, Kang L, Lee-Young RS, et al. Glucagon and lipid interactions in the regulation of hepatic AMPK signaling and expression of PPARα and FGF21 transcripts in vivo. Am J Physiol Endocrinol Metab. 2010;299(4):E607–E614.
38. Yu J, Zhao L, Wang A, et al. Growth hormone stimulates transcription of the fibroblast growth factor 21 gene in the liver through the signal transducer and activator of transcription 5. Endocrinology. 2012;153(2):750–758.
39. Chen W, Hoo RL, Konishi M, et al. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem. 2011; 286(40):34559–34566.
40. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fastinginduced hormone FGF 21. Cell Metab. 2008;8(1):77–83.
41. Owen BM, Bookout AL, Ding X, et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat Med. 2013;19(9): 1153–1156.
42. Tong X, Muchnik M, Chen Z, et al. Transcriptional repressor E4- binding protein 4 (E4BP4) regulates metabolic hormone fibroblast growth factor 21 (FGF21) during circadian cycles and feeding. J Biol Chem. 2010;285(47):36401–36409.
43. Durovcova V, Marek J, Hana V, et al. Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing’s syndrome. Physiol Res. 2010;59(3):415–422.
44. Laskewitz AJ, van Dijk TH, Bloks VW, et al. Chronic prednisolone treatment reduces hepatic insulin sensitivity while perturbing the fed-to-fasting transition in mice. Endocrinology. 2010;151(5): 2171–2178.
45. Yu H, Xia F, Lam KS, et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem. 2011;57(5):691–700.
46. Andersen B, Beck-Nielsen H, Hojlund K. Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin Endocrinol (Oxf). 2011;75(4):514–519.
47. Wildenhoff KE, Johansen JP, Karstoft H, Yde H, Sorensen NS. Diurnal variations in the concentrations of blood acetoacetate and 3-hydroxybutyrate. The ketone body peak around midnight and its relationship to free fatty acids, glycerol, insulin, growth hormone and glucose in serum and plasma. Acta Med Scand. 1974;195(1–2):25–28.
48. Ohshima K, Shargill NS, Chan TM, Bray GA. Adrenalectomy reverses insulin resistance in muscle from obese (ob/ob) mice. Am J Physiol. 1984;246(2Pt1):E193–E197.
49. Liu Y, Nakagawa Y, Wang Y, et al. Increased glucocorticoid receptor and 11-hydroxysteroid dehydrogβenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice. Diabetes. 2005;54(1):32–40.
50. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 β-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(1):285–291.
51. Torrecilla E, Fernandez-Vazquez G, Vicent D, et al. Liver upregulation of genes involved in cortisol production and action is associated with metabolic syndrome in morbidly obese patients. Obes Surg. 2012;22(3):478–486.
52. Li H, Fang Q, Gao F, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53(5):934–940.
53. Mraz M, Bartlova M, Lacinova Z, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf). 2009;71(3):369–375.
54. Zhang X, Yeung DC, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 2008;57(5):1246–1253.